Lexicon Pharmaceuticals, Inc. — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015; filed March 11, 2016. Lexicon is a clinical-stage biopharmaceutical company with no product sales to date. Revenue was primarily from collaborations and licenses.
Financial results and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $130.0 million | $22.9 million |
| Research and development expense | $95.2 million | $89.3 million |
| General and administrative expense | $23.8 million | $19.4 million |
| Operating income (loss) | $1.5 million | $(100.4) million |
| Net income (loss) | $(4.7) million | $(100.3) million |
| Net loss per share | $(0.05) | $(1.31) |
| Cash, cash equivalents and short-term investments | $521.4 million | $339.3 million |
| Working capital | $409.4 million | $324.0 million |
| Total debt | $105.8 million | $107.7 million |
- 2015 revenue included $129.7 million from collaborative agreements; Sanofi accounted for 98% of annual revenue. No revenue came from commercial product sales.
- Sanofi paid $300 million upfront for worldwide rights to develop, manufacture and commercialize sotagliflozin. Lexicon recognized $126.8 million for the license in 2015; the balance was allocated to future development services and funding obligations and is recognized over time.
- Fourth-quarter revenue was $127.3 million and net income was $86.8 million, versus a $2.9 million net loss in fourth-quarter 2014. The quarter’s results were heavily affected by Sanofi upfront-payment revenue recognition; Lexicon reported a full-year net loss.
- Cash provided by operating activities was $184.8 million, largely reflecting a $171.4 million increase in deferred revenue. Investing activities used $117.0 million, mainly for net investment purchases; financing activities used $2.0 million.
- Gross margin is not meaningfully reported because Lexicon had no product sales. The filing does not provide a clear product-sales margin.
- Debt included $87.5 million of 5.25% convertible senior notes due 2021 and an $18.3 million mortgage at 8.23%, with maturity in April 2017. Interest expense was $6.7 million, up from $2.3 million in 2014.
Material changes and business developments
- Revenue rose 469% year over year, principally because of the Sanofi agreement; 2014 revenue had primarily reflected the Ipsen collaboration. The 2015 improvement in reported loss does not represent recurring product profitability.
- R&D expense increased 7% to $95.2 million, driven by higher external clinical and nonclinical costs. G&A increased 23% to $23.8 million, including increased commercialization-preparation consulting costs.
- Lexicon reported building impairment charges of $3.6 million in 2015 and $13.1 million in 2014. The 2015 charge followed a change in the planned sale accounting treatment.
- In January 2016, Lexicon agreed to sell its Woodlands, Texas facilities for $21.2 million, subject to closing conditions and a leaseback arrangement for part of the property. The mortgage was expected to be repaid if the sale closed.
Outlook, risks and contingencies
- Telotristat etiprate: Both Phase 3 trials, TELESTAR and TELECAST, reported positive top-line results in 2015. Lexicon was preparing a U.S. regulatory application and potential launch. Approval was not assured; the FDA could require further evidence or trials. Ipsen holds commercialization rights outside the United States and Japan.
- Sotagliflozin: Lexicon was conducting three Phase 3 trials for type 1 diabetes and preparing with Sanofi for Phase 3 development in type 2 diabetes. Lexicon retained responsibility for type 1 diabetes clinical development and an option to co-promote in the U.S.; it agreed to fund up to $100 million toward planned type 2 diabetes development costs over three years.
- Sanofi agreement economics include up to $430 million in development and regulatory milestones, up to $990 million in sales milestones, and tiered royalties. These contingent amounts are not assured and were not recognized as revenue in 2015.
- Management said available resources and expected collaboration cash and revenues would fund planned operations for at least 12 months; the risk-factor discussion separately estimated at least two years. Actual runway depends on trial spending, milestones, commercialization costs and other factors.
- Lexicon had an accumulated deficit of $1.1 billion and expected continued losses and significant development spending. It cautioned that additional financing might be needed and could be unavailable on acceptable terms.
- Other material exposures include the $45 million maximum contingent obligation to Symphony Icon Holdings tied to certain telotristat-related licensing proceeds or approval, and potential Texas Enterprise Fund repayment of up to approximately $14.2 million for job-creation shortfalls, subject to credits.
- Key risks include clinical and regulatory failure or delay, dependence on Sanofi and Ipsen, competition, manufacturing and commercialization execution, reimbursement and pricing, intellectual-property disputes, and Invus ownership of approximately 59.6% of outstanding shares.
- The company reported effective disclosure controls and internal control over financial reporting; its auditor issued unqualified opinions on the financial statements and internal controls.
Most important facts for investors to verify
- Whether and when telotristat etiprate receives regulatory approval, and the final label, launch costs and commercial uptake.
- Progress, safety and outcomes of sotagliflozin’s Phase 3 trials, and the extent of Lexicon’s future development funding and any U.S. co-promotion decision.
- How much of the Sanofi upfront payment remains deferred, the timing of recognition, and whether future milestones or royalties are achieved.
- Cash burn excluding large collaboration receipts, the reconciliation of management’s 12-month and two-year runway statements, and debt service or refinancing needs.
- Closing terms and proceeds of the Texas facilities sale, including the leaseback and mortgage repayment, plus potential Symphony Icon and Texas Enterprise Fund payments.